PPARA and metabolic dysfunction-associated steatotic liver disease: However, recent clinical and preclinical studies with PPARα agonists such as fenofibrate and clofibrate suggested no significant improvement in NAFLD activity45 but rather showed that PPARα activation increases hepatic DNL and cholesterol accumulation46,47.